

Scientific Program » Thursday November 20, 2014

* = not CME-certified

09:00 a.m. - 10:45 a.m.

📌 APN-PA symposium - part 1

📍 Pompeii Ballroom

👤 Moderator: Kenneth Mitchell, MPAS, PA-C

09:00 a.m. - 09:05 a.m.

📌 Welcome/Program overview

Kenneth Mitchell, MPAS, PA-C

09:05 a.m. - 09:30 a.m.

📌 Post pelvic surgery/Radiation penile rehab/ Injection program

Joseph B. Narus, DNP, APRN, NP-BC &

Landon W. Trost, MD

09:30 a.m. - 09:55 a.m.

📌 Controversy with Testosterone Replacement Therapy (TRT)

Kevin Flinn, RN

09:55 a.m. - 10:20 a.m.

📌 Chronic orchialgia

Sijo J. Parekattil, MD

10:20 a.m. - 10:45 a.m.

📌 Penile implant - perioperative management

Brian S. Christine, MD

10:45 a.m. - 11:00 a.m.

📌 Break

📍 Ocean Tower I Foyer

11:00 a.m. - 12:15 p.m.

📌 APN-PA symposium - part 2

📍 Pompeii Ballroom

👤 Moderator: Kenneth Mitchell, MPAS, PA-C

11:00 a.m. - 11:25 a.m.

📌 Female sexual dysfunction

Brooke Faught, MSN, WHNP-BC

11:25 a.m. - 11:50 a.m.

📌 Genital piercings/mutilation

Jorge Caso, MD

11:50 a.m. - 12:15 p.m.

📌 Imaging in sexual medicine

Douglas F. Milam, MD

12:30 p.m. - 02:00 p.m.

📌 Sponsored lunch symposium

📍 Ocean Tower II B/C

02:00 p.m. - 02:05 p.m.

📌 Welcome

📍 Pompeii Ballroom

Lawrence S. Hakim, MD, FACS

02:05 p.m. - 02:10 p.m.

📌 Meeting overview

📍 Pompeii Ballroom

Tobias S. Köhler, MD, MPH

02:10 p.m. - 03:55 p.m.

📌 Lifestyle changes and sexual medicine: What should we really be telling our patients?

📍 Pompeii Ballroom

👤 Moderators: Kenneth Mitchell, MPAS, PA-C &
Christopher J. Wingard, PhD, MS

02:10 p.m. - 02:25 p.m.

📌 Introduction & basic science overview

Christopher J. Wingard, PhD, MS

Scientific Program

* = not CME-certified

02:25 p.m. - 02:40 p.m.

Cigarette smoking is a definitive risk factor for ED

Arthur L. Burnett II, MD & Hossein Sadeghi-Nejad, MD, FACS

02:40 p.m. - 02:55 p.m.

Diet & exercise effect on sexual med ED, low T

Jason M. Greenfield, MD

02:55 p.m. - 03:10 p.m.

The basic science of western diet & ED

Michael A. Adams, PhD

03:10 p.m. - 03:25 p.m.

Prostate and diet/lifestyle

Aaron Spitz, MD

03:25 p.m. - 03:40 p.m.

Biochemical and physiological basis of improvement in body composition & sexual function with lifestyle change and pharmacotherapy

Abdulmageed Traish, PhD

03:40 p.m. - 03:55 p.m.

Recent non sexual medicine landmark findings all sexual medicine providers must know

Martin Miner, MD

03:55 p.m. - 04:15 p.m.

ⓘ Break

📍 *Ocean Tower I*

04:15 p.m. - 05:30 p.m.

ⓘ ED & BPH treatments: New strategies, new snake-oils

📍 *Pompeii Ballroom*

👤 *Moderators: Eric L. Laborde, MD & Hossein Sadeghi-Nejad, MD, FACS*

04:15 p.m. - 04:30 p.m.

New BPH treatment paradigms

Kevin T. McVary, MD

04:30 p.m. - 04:45 p.m.

ED & SM supplements & internet drugs

William P. Conners, MD

04:45 p.m. - 05:00 p.m.

ESWL and ED

Trinity J. Bivalacqua, MD, PhD

05:00 p.m. - 05:10 p.m.



Podium presentation: 001.

Impact on sexual function and two year durability of the prostatic urethral lift: A multi-center, prospective, randomized study

Butcher, M.J.¹; Roehrborn, C.G.²; Gange, S.N.³; Bolton, D.M.⁴; Te, A.E.⁵; Shore, N.D.⁶; Chin, P.T.⁷; Rashid, P.⁸; Rukstalis, D.B.⁹; McVary, K.T.¹⁰

1: Southern Illinois University, USA; 2: University of Texas Southwestern Medical Center, USA; 3: Western Urological Clinic, USA; 4: Austin Hospital, Australia; 5: Weill Cornell Medical College, USA; 6: Carolina Urological Research Center, USA; 7: Figtree Private Hospital, Australia; 8: Port Macquarie Private Hospital, Australia; 9: Wake Forest Baptist Health, USA; 10: Southern Illinois University School of Medicine, USA

05:10 p.m. - 05:30 p.m.

Discussion

05:30 p.m. - 06:30 p.m.

ⓘ Female sexual medicine: New frontier

📍 *Pompeii Ballroom*

👤 *Moderators: Lawrence S. Hakim, MD, FACS & Johanna Hannan, PhD*

Scientific Program

* = not CME-certified

05:30 p.m. - 05:50 p.m.

1st Dr. Robert J. Krane annual lecture

Irwin Goldstein, MD

05:50 p.m. - 06:05 p.m.

Female sexual dysfunction & CAG repeats

Andrew T. Goldstein, MD, FACOG

06:05 p.m. - 06:20 p.m.

Basic science in FSD

Johanna Hannan, PhD

06:20 p.m. - 06:30 p.m.



Podium presentation: 002.

5 alpha reductase enzyme

deficiency: A new

pathophysiology of female sexual

dysfunction

Cohen, S.D.¹; Gonzalez, J.R.¹; Gagnon, C.¹; Minton, J.N.¹; Espenschied, C.²; Goldstein, I.³

1: San Diego Sexual Medicine, USA; 2: San Diego Sexual Medicine, United States; 3: Alvarado Hospital, USA

06:30 p.m. - 08:00 p.m.

📍 Welcome reception

📍 *Ocean Tower I*

Scientific Program » Friday November 21, 2014

* = not CME-certified

06:45 a.m. - 07:45 a.m.

📌 Sponsored breakfast symposium

📍 *Ocean Tower II B/C*

07:45 a.m. - 08:00 a.m.

📌 Day introduction and recap of Thursday

📍 *Pompeii Ballroom*

Tobias S. Köhler, MD, MPH

08:00 a.m. - 09:00 a.m.

📌 Psychology and sexual dysfunction

📍 *Pompeii Ballroom*

👤 *Moderators: Stanley Althof, PhD, IF & Christian Nelson, PhD*

08:00 a.m. - 08:15 a.m.

Psychiatric drugs in sexual medicine: The good, the bad and the ugly

Bonnie R. Saks, MD

08:15 a.m. - 08:30 a.m.

The cursed penis: Optimizing surgical patient selection

Landon W. Trost, MD

08:30 a.m. - 08:45 a.m.

Key concepts & questions to optimize diagnosis & treatment of sexual dysfunction

Michael A. Perelman, PhD

08:45 a.m. - 08:55 a.m.



Podium presentation: 003.
Effect of testosterone solution
2% for the treatment of
ejaculatory dysfunction in
androgen-deficient men*

Paduch, D.A.¹; Polzer, P.²; Ni, X.²; Basaria, S.³

1: Weill Cornell Medical College, USA; 2: Eli Lilly and Company, USA; 3: Harvard Medical School, USA

08:45 a.m. - 08:55 a.m.



Podium presentation: 004.
Prevalence of ejaculatory
dysfunctions as a function of
testosterone*

Paduch, D.A.¹; Polzer, P.²; Morgentaler,

A.³; Althof, S.E.⁴; Ni, X.²; Patel, A.B.²; Basaria, S.³

1: Weill Cornell Medical College, USA; 2: Eli Lilly and Company, USA; 3: Harvard Medical School, USA; 4: Center for Marital and Sexual Health of South Florida, USA

08:45 a.m. - 08:55 a.m.



Podium presentation: 005.
Perceived sexual dissatisfaction
with ejaculatory dysfunctions*

Paduch, D.A.¹; Polzer, P.²;

Morgentaler, A.³; Althof, S.E.⁴; Ni, X.²; Patel, A.B.²; Basaria, S.³

1: Weill Cornell Medical College, USA; 2: Eli Lilly and Company, USA; 3: Harvard Medical School, USA; 4: Center for Marital and Sexual Health of South Florida, USA

09:00 a.m. - 10:30 a.m.

📌 Truths in testosterone

📍 *Pompeii Ballroom*

👤 *Moderators: Mohit Khera, MD & Tobias S. Köhler, MD, MPH*

09:00 a.m. - 09:20 a.m.

Testosterone replacement and CV risks

Abraham Morgentaler, MD

09:20 a.m. - 09:40 a.m.

The role of estrogen and SHBG

Michael P. Finkelstein, MD

09:40 a.m. - 10:10 a.m.

The realities and secrets of anabolic steroid abuse

Chad Schaive

Scientific Program

* = not CME-certified

10:10 a.m. - 10:20 a.m.



Podium presentation: 006.
A descriptive analysis to compare the occurrence of myocardial infarction in testosterone-treated and untreated hypogonadal

males and PDE5-inhibitor users*

Li, H.¹; Benoit, K.¹; Michael, J.¹; Motsko, S.¹

1: Eli Lilly and Company, USA

10:20 a.m. - 10:30 a.m.



Podium presentation: 007.
Clomiphene citrate is superior to anastrozole in raising testosterone in hypogonadal infertile men: A prospective

randomized double blind comparison trial

Helo, S.¹; Mechlin, C.²; Alkaram, A.³; McCullough, A.³

1: Albany Medical Center, USA; 2: Urology Associates of Central Missouri, USA; 3: The Urologic Institute of Northeastern New York, USA

10:30 a.m. - 10:55 a.m.

📌 Break & poster viewing time

📍 *Ocean Tower I*

10:55 a.m. - 11:55 a.m.

📌 Moderated posters 1 – Androgens & Hypogonadism 1

» *Concurrent session*

📍 *Ocean Tower II A*

👤 *Moderators: Andrew R. McCullough, MD & Abraham Morgentaler, MD*



030. Change in hematocrit during treatment of hypogonadism via implantable testosterone pellets

Hayden, R.¹; Bennett, N.²; Tanrikut, C.¹

1: MGH, USA; 2: Lahey Clinic, USA



031. Daily dose and costs associated with maintenance therapy of topical testosterone agents among hypogonadal men*

Kaltenboeck, A.¹; Boytsov, N.²;

Hayes-Larson, E.¹; San Roman, A.M.¹; Ivanova, J.¹; Birnbaum, H.G.¹; Foster, S.A.²; Vazquez, J.A.²; Muram, D.²; Swindle, R.W.²

1: Analysis Group, Inc, USA; 2: Eli Lilly and Co, USA

1: Analysis Group, Inc, USA; 2: Eli Lilly and Co, USA



032. Hypogonadism in the infertile population: Different or the same?

Levey, H.R.¹; Kukreja, J.¹; Kucherov, V.¹; Smith, A.¹; Ramasamy, R.²;

Gentile, D.¹; Fung, C.¹; O'Brien, J.¹

1: University of Rochester, Rochester, NY, USA; 2: Baylor College of Medicine, Houston TX, USA



033. Pharmacokinetics and efficacy of a new SEDDS formulation of oral Testosterone Undecanoate (TU) in hypogonadal men: Data from two phase 3 trials with different dose-titration algorithms*

Swerdloff, R.S.¹; Salameh, W.²; Dobs, A.³; Longstreth, J.⁴; Faulkner, S.²; Dudley, R.²; Flippo, G.⁵; Kaminetsky, J.⁶; Amory, J.⁷; Danoff, T.²; Honig, S.H.⁸; Wang, C.⁹

1: UCLA, USA; 2: Clarus Therapeutics, USA; 3: Johns Hopkins, USA; 4: Longstreth and Assoc, USA; 5: Alabama Clinical Therapeutics, USA; 6: University Urology Assoc, USA; 7: University of Washington, USA; 8: Yale University; 9: Ucla, USA



034. Low testosterone at time of transplant independently predicts poor patient and graft survival in male renal transplant recipients

Shoskes, D.¹; Kerr, H.¹; Askar, M.¹;

Goldfarb, D.¹; Schold, J.¹

1: Cleveland Clinic, USA

Scientific Program

* = not CME-certified



035. Application of the Endocrine Society clinical guidelines on testosterone therapy in men with androgen deficiency syndromes in clinical practice*

Muram, D.¹; Matsumoto, A.²; Zhang, X.¹; Cui, Z.¹

1: Lilly Research Laboratories, USA; 2: Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, USA



036. HCG can assist with recovery of spermatogenesis after testosterone use

Wenker, E.P.¹; Dupree, J.M.¹; Langille, G.M.¹; Kovac, J.¹;

Ramasamy, R.¹; Lamb, D.¹; Mills, J.N.²; Lipshultz, L.I.¹

1: Baylor College of Medicine, USA; 2: The Urology Center of Colorado, USA



037. Androgen receptor CAG repeat length polymorphism is associated with risk of metabolic syndrome in a Korean male

Kim, J.W.¹; Bae, Y.D.¹; Yoon, C.Y.¹;

Kim, J.J.¹; Moon, D.G.¹

1: Korea University College of Medicine, Korea, South



038. The effect of testosterone restorative therapy (TRES) on testicular volume. Results from a double blind randomized 12 week trial of clomiphene citrate

vs anastrozole

McCullough, A.¹; Xu, R.²; Helo, S.²; Elebyjian, L.²; Feustel, P.²

1: Albany Medical College, USA; 2: Albany Medical College



039. Association between testosterone therapy and thrombotic events in elderly men

Ramasamy, R.¹; Scovell, J.²; Mederos, M.²; Mai, C.¹; Cross, R.¹;

Ran, R.¹; Besada, S.¹; Lipshultz, L.¹

1: Baylor College of Medicine, USA; 2: Baylor College of Medicine, USA



040. Effect of testosterone supplementation on symptoms in men with hypogonadism

Wilken, N.¹; Scovell, J.¹; Ramasamy, R.¹; Lipshultz, L.¹

1: Baylor College of Medicine, USA

10:55 a.m. - 11:55 a.m.

ⓘ Moderated posters 2 – BPH & Ejaculation

» Concurrent session

📍 Mona Lisa

👤 Moderators: Eric L. Laborde, MD & Alan W. Shindel, MD



041. Delayed ejaculation remains a recalcitrant condition: Results of a SMSNA survey

Butcher, M.¹; Sadowski, D.¹;

Botchway, A.¹; Welliver, C.¹; Kohler, T.¹

1: Southern Illinois University SOM, USA



042. Sexual function associated with lower urinary tract symptoms in men with benign prostatic hyperplasia: MTOPS cohort of cross-sectional and

longitudinal data

Butcher, M.¹; Fwu, C.²; Kirkali, Z.³; Kohler, T.⁴;

Burrows, P.⁵; Eggers, P.³; Kusek, J.³; McVary, K.⁴

Scientific Program

* = not CME-certified

1: Southern Illinois University, USA; 2: Social & Scientific Systems, Inc., Silver Spring, MD, USA; 3: Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA; 4: Department of Urology, Southern Illinois University, Springfield, IL, USA; 5: The George Washington University Biostatistics Center, Rockville, MD, USA



043. Acceptance of a pre-operative educational seminar about recovery from side-effects after prostate cancer surgery

Paich, K.¹; Dunn, R.¹; Skolarus, T.¹;

Montie, J.¹; Palapattu, G.¹; Wood, D.²; Mitchell, S.¹; Hola, V.¹; Erickson, K.¹; Shifferd, J.¹; Wittmann, D.¹
1: University of Michigan, USA; 2: Beaumont Health System, USA



044. Crossover study of the prostatic urethral lift: Analysis of lower urinary tract symptoms

Gange, S.N.¹; Cantwell, A.L.²; Shore, N.D.³; Fagelson, J.E.⁴; Woo, H.H.⁵; Barkin, J.⁶; Dowling, W.T.⁷; Chin, P.T.⁸

1: Western Urological Clinic, USA; 2: Atlantic Urological Associates, USA; 3: Carolina Urological Research Center, USA; 4: Urology Associates of Denver, USA; 5: University of Sydney, Australia; 6: University of Toronto, Canada; 7: Chesapeake Urology, USA; 8: Figtree Private Hospital, Australia



045. Effects of tamsulosin on premature ejaculation in men with LUTS/BPH

Hyun, J.S.¹; Kam, S.C.¹; Jae, S.W.¹; Yun, S.¹

1: Gyeongsang National University Hospital



046. Screening for low testosterone during urology office visits without referral for hypogonadism

Sauer, A.¹; Omarbasha, B.²; Mouraviev, V.³

1: Binghamton University, USA; 2: Upstate University, USA; 3: AMP Urology, USA



047. Non-medicinal components are an important factor in drug delivery in topical therapies: A study of topical lidocaine therapy for premature ejaculation

Garcia, F.¹; Capomacchia, A.²; Kongkeo, S.³; Brock, G.⁴

1: University of Saskatchewan, Cypress Health Region, Canada; 2: University of Georgia, College of Pharmacy, Athens, GA, U.S.A.; 3: Absorption Pharmaceutical, Huntington Beach, CA, U.S.A.; 4: Western University, St. Joseph's Health Care, London, ON, Canada



048. Low T predicts worse LUTS: Final results of the CUPPID study

Kottwitz, M.¹; Koenig, J.¹; Stevenson, B.¹; Sulaver, R.¹; Bednarchik, C.¹; Welliver Jr, C.²;

McVary, K.¹; Kohler, T.S.¹

1: Southern Illinois University SOM, USA; 2: Albany Medical Center



049. Buspirone in the treatment of chronic orchalgia

Liaw, A.¹; Lowe, G.¹

1: Ohio State University, USA



050. Trigger point injections: A new treatment strategy for sexual pain

Bahlani, S.¹; Moldwin, R.¹; King, A.¹

1: North Shore-LIJ, USA

Scientific Program

* = not CME-certified



051. Characterization of voiding dysfunction in adults with sickle cell disease

Anele, U.¹; Morrison, B.F.²; Burnett, A.L.¹

1: Brady Urological Institute, The Johns Hopkins School of Medicine, USA; 2: University of the West Indies, Jamaica

12:00 p.m. - 01:30 p.m.

☰ SMSNA lunch and learn symposium - Contemporary management of Peyronie's disease: An interactive case-based lunch and learn symposium

📍 Ocean Tower II B/C

👤 Moderator: John P. Mulhall, MD

The CME-certified symposium will consist of three case presentations, the use of audience response system (ARS) and open questions and answers

Wayne J.G. Hellstrom, MD, David Ralph, MS, FRCS & Landon W. Trost, MD

01:30 p.m. - 03:50 p.m.

☰ Translational perspective on the role of testosterone in sexual function and dysfunction (white paper session)

» Concurrent session

📍 Pompeii Ballroom

👤 Moderators: Michael E. DiSanto, PhD & Carol A. Podlasek, PhD

01:30 p.m. - 01:40 p.m.

Introduction and clinical role of testosterone

John P. Mulhall, MD

01:40 p.m. - 01:55 p.m.

Physiological role of testosterone

Kelvin Davies, BSc, MSc, PhD &

John P. Mulhall, MD

01:55 p.m. - 02:10 p.m.

Development & penile morphology on testosterone

Carol A. Podlasek, PhD &

Christopher J. Wingard, PhD, MS

02:10 p.m. - 02:25 p.m.

Autonomic input and testosterone

Trinity J. Bivalacqua, MD, PhD &

Johanna Hannan, PhD

02:25 p.m. - 02:40 p.m.

Testosterone impact/association RRP, diabetes and aging

Mohit Khera, MD &

Biljana Musicki, PhD

02:40 p.m. - 02:55 p.m.

PDE5i and testosterone

Michael E. DiSanto, PhD &

Nestor Gonzalez-Cadavid, PhD

02:55 p.m. - 03:10 p.m.

Summary and clinical integration

Arthur L. Burnett II, MD

03:10 p.m. - 03:20 p.m.



Podium presentation: 008. Low osteocalcin levels are associated with androgen deficiency

Le, B.¹; Billups, K.²; Anele, U.²;

Burnett, A.L.²

1: Meriter Medical Group, USA; 2: Brady Urological Institute, Johns Hopkins Hospital, USA

Scientific Program

* = not CME-certified

03:10 p.m. - 03:20 p.m.



Podium presentation: 009.
Determining serum levels of osteocalcin in a rat model of hypogonadism

Le, B.¹; Chen, H.²; Burnett, A.L.³;

Zirkin, B.²

1: Meriter Medical Group, USA; 2: Bloomberg School of Public Health, Johns Hopkins University, USA; 3: Brady Urological Institute, Johns Hopkins Hospital, USA

03:20 p.m. - 03:30 p.m.



Podium presentation: 010.
Comparison of the effects of testosterone gels, injections and pellets on serum hormones, erythrocytosis, lipids, and

prostate specific antigen

Pastuszak, A.W.¹; Gomez, L.P.¹; Scovell, J.M.¹; Khera, M.¹; Lipshultz, L.I.¹

1: Baylor College of Medicine, USA

03:30 p.m. - 03:50 p.m.

Q&A

01:30 p.m. - 03:50 p.m.

APN/PA hands on session

» *Concurrent session*

📍 *Key Biscayne*

👤 *Moderator: Kenneth Mitchell, MPAS, PA-C*

Injections/Priapism

Joseph B. Narus, DNP, APRN, NP-BC

Xiaflex®

Kenneth Mitchell, MPAS, PA-C

Male genital examination

Jeffrey Albaugh, PhD, APRN, CUCNS

Implant training

Brian S. Christine, MD

VED

Tim Irizarry, PA-C

03:50 p.m. - 04:00 p.m.

Journal of Sexual Medicine update*

📍 *Pompeii Ballroom*

John P. Mulhall, MD

04:00 p.m. - 05:00 p.m.

Sponsored afternoon symposium

📍 *Ocean Tower II B/C*

05:00 p.m. - 05:15 p.m.

Poster viewing time*

📍 *Mona Lisa & Ocean Tower II A*

05:15 p.m. - 06:15 p.m.

Moderated posters 3 – Androgens & Hypogonadism 2

» *Concurrent session*

📍 *Ocean Tower II A*

👤 *Moderators: Michael P. Finkelstein, MD & Mohit Khera, MD*



052. Testosterone therapy after radiation therapy for low, intermediate, and high risk prostate cancer

Pastuszak, A.W.¹; Khanna, A.²;

Badhiwala, N.³; Morgentaler, A.⁴; Hulth, M.⁵; Conners, W.P.⁵; Sarosdy, M.⁶; Carrion, R.⁷; Lipshultz, L.I.¹; Khera, M.¹

1: Baylor College of Medicine, USA; 2: Cleveland Clinic Foundation, USA; 3: Washington University in St. Louis, USA; 4: Harvard Medical School, USA; 5: Men's Health Boston, USA; 6: South Texas Urology, USA; 7: University of South Florida, USA

Scientific Program

* = not CME-certified



053. Testosterone replacement therapy in opioid-induced hypogonadal men: A prospective analysis

Sisul, D.¹; Acevedo, J.¹; Raheem,

O.¹; Hsieh, T.¹

1: UCSD Health System, USA



058. The effect of testosterone topical solution in hypogonadal men with suboptimal response to a topical testosterone gel*

Seftel, A.¹; Kim, E.²; Ruff,

D.³; Burns, P.³

1: Cooper Medical School of Rowan University, USA; 2:

Department of Urology and Urologic Surgery, University of

Tennessee Graduate School of Medicine, USA; 3: Eli Lilly and

Company, USA



054. Effect of testosterone replacement therapy on lipid profile in the patients with testosterone deficiency syndrome

Han, K.¹; Ahn, T.Y.²

1: Asan medical center, Korea, South; 2: Asan Medical Center,

Korea, South



059. Identifying factors affecting the variability of testosterone levels post therapy

Chakrabarty, A.¹; Panda,

S.²; Nicholas, J.³

1: Urologic Clinics of North Alabama, United States; 2: SCB

Medical College; 3: Urologic Clinic of North Alabama



055. Influence of altitude on the rise hematocrit on patients receiving testosterone therapy: The low T experience

Schmidhuber, J.¹; Tan, R.¹

1: Low T Center, USA



060. Early experience with testosterone replacement therapy after radiation therapy for prostate cancer

Berookhim, B.¹; Krishnan, R.²;

Nelson, C.J.²; Mulhall, J.P.²

1: Lenox Hill Hospital, USA; 2: Memorial Sloan Kettering Cancer

Center, USA



056. Factors that influence hypogonadal men to initiate testosterone replacement therapy*

Rosen, R.C.¹; Seftel, A.D.²; Ruff,

D.D.³; Muram, D.³

1: New England Research Institute, USA; 2: Cooper University

Hospital, USA; 3: Eli Lilly and Company, USA



061. Efficacy and compliance with Anastrozole for the treatment of late onset hypogonadism

Le, S.¹; Feustel, P.; McCullough, A.

1: Albany Medical College, USA



057. Testosterone restorative therapy in a urologic practice

Ellen, J.¹; McCullough, A.¹

1: Albany Medical Center, USA



062. Utilization patterns of parenteral testosterone preparations in hypogonadal men*

Donatucci, C.¹; Cui, Z.¹; Zhu, Y.¹;

Fang, Y.²; Muram, D.¹

1: Eli Lilly and Company, USA; 2: InVentiv Health Clinical, USA

Scientific Program

* = not CME-certified



063. Enclomiphene citrate raises testosterone in hypogonadal men and lowers LDL cholesterol*

Fontenot, G.¹; Wiehle, R.¹; Thompson, J.¹; Sandel, M.¹; Nydell, J.¹; Cunningham, G.²; Podolski, J.¹

1: Repros Therapeutics Inc., USA; 2: Baylor College of Medicine



066. Selection criteria used to guide surgical approach for management of Peyronie's disease: A single institution experience

Papagiannopoulos, D.¹; Yura, E.¹;

Levine, L.¹

1: Rush University Medical Center, USA

05:15 p.m. - 06:15 p.m.

Moderated posters 4 – Peyronie's disease

» Concurrent session

📍 Mona Lisa

👤 Moderators: William O. Brant, MD & Joshua A. Broghammer, MD



064. Changes in the effects of Peyronie's disease after treatment with collagenase clostridium histolyticum according to men with Peyronie's

disease and their female sexual partners*

Goldstein, I.¹; Knoll, D.²; Lipshultz, L.I.³; Tursi, J.P.⁴; Smith, T.M.⁴; Kaufman, G.J.⁴; Gilbert, K.⁴; Rosen, R.C.⁵; McMahon, C.G.⁶

1: San Diego Sexual Medicine, San Diego, CA, USA; 2: Center for Urological Treatment, Nashville, TN, USA; 3: Baylor College of Medicine, Houston, TX, USA; 4: Auxilium Pharmaceuticals, Chesterbrook, PA, USA; 5: New England Research Institutes, Inc., Watertown, MA, USA; 6: Australian Centre for Sexual Health, St. Leonards, NSW, Australia



067. The effect of urethroplasty on Peyronie's disease

Austenfeld, M.¹; Broghammer, J.¹

1: University of Kansas, USA



068. The Modified Sliding Technique (MoST) for penile lengthening with penile prosthesis insertion

Valenzuela, R.¹; Weinberg, A.¹; Deibert, C.¹; Hernandez, K.¹; Egydio, P.²

1: Columbia University Medical Center, USA; 2: University of Sao Paulo, Brazil



069. Meaningful change in Peyronie's disease following treatment with collagenase clostridium histolyticum: Results from two large double-blind,

randomized, placebo-controlled phase 3 studies*

Carson III, C.¹; Gittelman, M.²; Tan, R.³; Tursi, J.P.⁴; Smith, T.M.⁴; Kaufman, G.J.⁴; Jones, N.A.⁵; Hellstrom, W.J.G.³

1: University of North Carolina School of Medicine, USA; 2: South Florida Medical Research, Aventura, USA; 3: Tulane University Health Sciences Center, USA; 4: Auxilium Pharmaceuticals, Inc, USA; 5: Auxilium Pharmaceuticals, Inc, UK



065. Qualitative analysis of Peyronie's disease partner burden

Nelson, C.¹; Hardin, C.²; Hardin, S.²; Bauler, V.²; Baum, V.²; Buehler, S.³; Gutterman, R.²; Mulhall, J.¹

1: Memorial Sloan Kettering Cancer Center, USA; 2: Association of Peyronie's Disease Advocates, USA; 3: The Buehler Institute, USA

Scientific Program

* = not CME-certified



070. Intralesional interferon α -2b therapy for Peyronie's disease: Penile duplex findings and clinical observations

Tapscott, A.¹; Hakim, L.²

1: Carolina Urology Partners, USA; 2: Cleveland Clinic Florida, USA



071. Biomaterial grafting with penile prosthetic insertion in the management of Peyronie's disease: Efficacy and safety

Knoll, L.D.¹

1: USA



072. Surgical therapy of Peyronie's disease by partial plaque excision and grafting with collagen fleece: long-term results

Hatzichristodoulou, G.¹; Fiechtner,

S.¹; Gschwend, J.E.¹; Lahme, S.²

1: Department of Urology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany; 2: Department of Urology, Siloah St. Trudpert Hospital, Pforzheim, Germany



073. Peyronie's disease (PD) and penile hemodynamics: Color duplex doppler ultrasound analysis of PD patients

Pathak, R.¹; Chavers, R.¹; Broderick,

G.²

1: Mayo Clinic, USA; 2: Mayo Clinic, USA



074. Ventral intralesional verapamil injections for Peyronie's disease: Feasibility and safety

Berookhim, B.¹; Chevinsky, M.²;

Jakubowski, C.²; Larish, Y.¹; Nelson, C.J.²; Mulhall, J.P.²

1: Lenox Hill Hospital, USA; 2: Memorial Sloan Kettering Cancer Center, USA



075. Peyronie's disease symptom bother reduction is related to penile curvature improvement in response to treatment with collagenase clostridium

histolyticum: Results from two large double-blind, randomized, placebo-controlled phase 3 studies*

Lipshultz, L.I.¹; Sadeghi-Nejad, H.²; Mills, J.³; Tursi, J.P.⁴; Smith, T.M.⁴; Kaufman, G.J.⁴; Liu, G.⁴; Honig, S.⁵

1: Baylor College of Medicine, Houston, TX, USA; 2: Center for Male Reproductive Medicine, Hackensack, NJ, USA; 3: The Urology Center of Colorado, Denver, CO, USA; 4: Auxilium Pharmaceuticals, Chesterbrook, PA, USA; 5: Yale University School of Medicine, New Haven, CT, USA

07:00 p.m. - 11:00 p.m.

‡ Taste of Miami (ticket not included in registration fee)

Scientific Program » Saturday November 22, 2014

* = not CME-certified

06:45 a.m. - 07:45 a.m.

☰ Sponsored breakfast symposium

📍 *Ocean Tower II B/C*

07:45 a.m. - 08:00 a.m.

☰ Day introduction and recap of Friday

📍 *Pompeii Ballroom*

Tobias S. Köhler, MD, MPH

08:00 a.m. - 09:40 a.m.

☰ Peyronie's/Reconstruction/Post RRP - part 1

📍 *Pompeii Ballroom*

👤 *Moderators: Anthony J. Bella, MD & William O. Brant, MD*

08:00 a.m. - 08:50 a.m.

3 Worst complications of my career & what I would have done differently

Sean Elliott, MD, MS, Laurence A. Levine, MD & Kurt McCammon, MD

08:50 a.m. - 09:40 a.m.

Controversial point/counterpoint: Simultaneous sling/aus IPP placement: Should be the default choice?

Brian S. Christine, MD

Controversial point/counterpoint: Complex continence: conventional AUS is not always the answer

Joshua A. Broghammer, MD

Controversial point/counterpoint: Alternative Peyronie's treatments – Are ESWL & collagen fleece ready for “prime time”?

Georgios Hatzichristodoulou, MD, FEBU, FECSM

Controversial point/counterpoint: Grafting materials: have we found the perfect material?

Nelson Bennett Jr., MD

09:40 a.m. - 10:05 a.m.

☰ ESSM sponsored debate - Targeted therapy for rehabilitation: Is this the future

📍 *Pompeii Ballroom*

👤 *Moderators: Serge Carrier, MD & David Ralph, MS, FRCS*

Nerve side

Maarten Albersen, MD

Endothelium side

John P. Mulhall, MD

10:05 a.m. - 10:50 a.m.

☰ Peyronie's/Reconstruction/Post RRP - part 2

📍 *Pompeii Ballroom*

👤 *Moderators: Anthony J. Bella, MD & William O. Brant, MD*

10:05 a.m. - 10:15 a.m.



Podium presentation: 011. TNF-alpha is increased in major pelvic ganglion of rats following bilateral cavernous nerve injury and impairs neurite outgrowth ex vivo

Matsui, H.¹; Hannan, J.L.¹; Liu, X.¹; Bivalacqua, T.J.¹

1: The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine

Scientific Program

* = not CME-certified

10:15 a.m. - 10:25 a.m.



Podium presentation: 012.
Frequency of Intracavernosal Injections (ICI) improves Erectile Function Recovery (EFR) following Radical Prostatectomy (RP)

Nelson, C.¹; Pessin, H.¹; Mulhall, J.¹

1: Memorial Sloan Kettering Cancer Center, USA

10:25 a.m. - 10:40 a.m.

ISSM sponsored lecture - Strategies for penile prosthesis placement in PD and corporal fibrosis

Wayne J.G. Hellstrom, MD

10:40 a.m. - 10:50 a.m.



Podium presentation: 013.
A new non invasive approach for the treatment of acute phase Peyronie's disease – A prospective, randomized, double-blind, placebo-

controlled study evaluating the safety and efficacy of topically applied gel H-100 which combines Nicardipine, Superoxide Dismutase and Emu Oil

Twidwell, J.¹; Levine, L.²

1: Urology Associates LTD, USA; 2: Rush University

10:50 a.m. - 11:10 a.m.

📍 Break & poster viewing time

📍 Ocean Tower I

11:10 a.m. - 12:10 p.m.

📍 Moderated posters 5 – ED diagnosis & Medical treatment

» *Concurrent session*

📍 Ocean Tower II A

👤 Moderators: Nelson Bennett Jr., MD & Run Wang, MD



076. The efficacy of Avanafil in subjects with intercourse attempts within 15 minutes after dosing*

Belkoff, L.H.¹; Tursi, J.P.²; Uy, J.²;

Smith, T.M.²; Nejat, R.J.³

1: Urologic Consultants of SE PA, Bala Cynwyd, PA, USA; 2:

Auxilium Pharmaceuticals, Inc., Chesterbrook, PA, USA; 3: School of Medicine at the State University of New York, Stony Brook, NY, USA



077. A comparison of baseline erectile function after on-demand 20 mg tadalafil vs. daily 5 mg tadalafil in men with erectile dysfunction and diabetes: A

prospective, observational 2-year study

Park, H.J.¹; Park, N.C.¹

1: Pusan National University Hospital, Korea, South



078. Cavernous Venous Occlusive Disease (CVOD) and Color Doppler Duplex Ultrasound (CDDU) analysis: What CDDU parameters are associated with CVOD

Pathak, R.¹; Chavers, R.¹; Broderick, G.¹

1: Mayo Clinic, USA



079. Successful intercourse in men with erectile dysfunction within the first three doses of Avanafil*

Goldstein, I.¹; Karlin, G.S.²; Tursi,

J.P.³; Uy, J.³; Smith, T.M.³; Kaminetsky, J.⁴

1: San Diego Sexual Medicine, San Diego, CA, USA; 2: Urology

Care Alliance/Advanced Research, Lawrenceville, NJ, USA;

3: Auxilium Pharmaceuticals, Inc., Chesterbrook, PA, USA; 4:

University Urology Associates, New York, NY, USA

Scientific Program

* = not CME-certified



080. Couples' treatment satisfaction following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily*

Burns, P.R.¹; Rosen, R.C.²; Dunn, M.³; Baygani, S.K.¹; Perelman, M.A.⁴

1: Eli Lilly and Company, USA; 2: New England Research Institutes, Inc., USA; 3: SUNY - Brooklyn Downstate Medical Center, USA; 4: NY Weill Cornell Medical Center, USA



081. Erectile dysfunction, testosterone, and C-reactive protein are associated with progression of metabolic syndrome over time

Escolin, N.¹; Iyengar, R.L.¹; Maceda, C.¹; O'Boyle, K.¹; Thapi, S.¹; Woodward, M.²; Crowley, L.¹; Bar-Chama, N.¹; McLaughlin, M.A.¹

1: Ichan School of Medicine at Mount Sinai, USA; 2: University of Oxford



082. Predictors of erectile response in patients with arterial disease on penile doppler ultrasound

McCraw, C.¹; Fox, P.¹; Cutler, C.¹; Ostrowski, A.¹; Li, Q.¹; Klaassen, Z.¹; Lewis, R.W.¹

1: Georgia Regents University, USA



083. Factors correlating with sexual interest and function in long-term colorectal cancer survivors

Westney, O.L.¹; Ayoub, H.¹; You, Y.¹; Tran Cao, H.S.¹; Hu, C.Y.¹; Chang, G.¹; Feig, B.¹; Rodriguez-Bigas, M.¹; Skibber, J.¹

1: MD Anderson Cancer Center, USA



084. Udenafil for the treatment of erectile dysfunction: Results from two pivotal studies*

Mills, J.¹; Bernstein, A.²; Thomas, H.³; Platt, C.²; Sniukiene, V.²; Hoel, G.³

1: Center for Men's Health at The Urology Center of Colorado; 2: Actavis plc; 3: Actavis Inc



085. Pre-treatment counseling on quality of life issues before management of prostate malignancy

Rankin-Wagenaar, R.¹; Durbin-Johnson, B.¹; Dall'era, M.¹; Valicenti, R.¹; Shindel, A.¹

1: University of California, Davis, USA



086. The efficacy of long-term daily dosage of alfuzosin 10 mg upon sexual function of BPH patients: 2-year prospective observational

Hyun, J.S.¹; Kam, S.C.¹; Choi, S.M.¹; Yun, S.¹

1: Gyeongsang National University Hospital

11:10 a.m. - 12:10 p.m.

ⓘ Moderated posters 6 – Implant 1

» Concurrent session

📍 Mona Lisa

👤 Moderators: David Ralph, MS, FRCS & Doron S. Stember, MD



087. Implant length – Baseline characteristic correlations

Bennett, N.E.¹; Bella, A.J.²; Karpman, E.³; Brant, W.O.⁴; Jones, L.⁵; Kansas, B.⁶; Kohler, T.⁷; Khera, M.⁸

1: Lahey Hospital and Medical Center, USA; 2: University of Ottawa; 3: El Camino Urology; 4: University of Utah; 5: Urology San Antonio; 6: The Urology Team; 7: Southern Illinois University; 8: Baylor College of Medicine

Scientific Program

* = not CME-certified



088. Validation of a prediction model for penile prosthesis implantation for erectile dysfunction management

Anele, U.¹; Segal, R.L.¹; Le, B.V.¹;

Burnett, A.L.¹

1: Brady Urological Institute, The Johns Hopkins School of Medicine, USA



089. Use of magnetic induction to activate a shape memory alloy penile prosthesis

Colombo, A.¹; Le, B.²; McVary, K.¹

1: SIU, USA; 2: MERITER Health services



090. The Carrion Cast: An update on the usage of the intracorporeal antimicrobial doped spacer for the treatment of penile implant infection

Martinez, D.¹; Alhammali, E.¹; Emtage, J.¹; Perito, P.²; Parker, J.¹; Carrion, R.¹

1: University of South Florida, USA; 2: Perito Urology, USA



091. The Medtronic Zotarolimus-ELuting Peripheral Stent System for the treatment of ED in males with sub-optimal response to PDE5 inhibitor - 3 year results*

Kohler, T.¹; Goldstein, I.²

1: Southern Illinois University SOM, USA; 2: Institute for Sexual Medicine, USA



092. Observation of local clinical penile prostheses infections instead of immediate salvage rescue/removal: Ten center study with surprising results

Henry, G.¹; Price, G.²; Pryor, M.³; Greenfield, J.⁴; Jones, L.⁵; Perito, P.⁶; Morey, A.⁷; Goldstein, I.⁸; Bella, A.⁹; Kohler, T.¹⁰; Land, S.¹¹; Berger, A.¹²; Cohen, S.¹³

1: Regional Urology, USA; 2: American Medical Systems, USA; 3: Urology Center of Spartanburg; 4: Urology Associates of North Texas, USA; 5: Urology San Antonio, USA; 6: Perito Urology, USA; 7: University of Texas Southwestern, USA; 8: San Diego Sexual Medicine, USA; 9: Ottawa Hospital Research Institute, USA; 10: SIU School of Medicine, USA; 11: Lake Shore Urology, USA; 12: Associated Urological Specialists, USA; 13: Advanced Urological Care P.C., USA



093. Wound complications in inflatable penile prosthesis with scrotoplasty

Sulaver, R.¹; Butcher, M.¹; Kottwitz, M.¹; Frederick, L.¹; Welliver, C.¹;

Kohler, T.¹

1: Southern Illinois University SOM, USA



094. Long acting bupivacaine decreases peri-operative narcotic requirements in men undergoing penile prosthesis implantation

Hanerhoff, B.¹; Welliver Jr, R.C.²; Brahmamdam, A.³; Cummins, C.⁴; Bednarchik, C.L.¹; Mueller, G.¹; Dynda, D.¹; Kohler, T.S.¹

1: Southern Illinois University SOM, USA; 2: Albany Medical Center, USA; 3: St Andrews Hospital, USA; 4: Saint Johns Hospital, USA



095. Is risk of AUS cuff erosion higher in patients with penile prosthesis?

French, D.C.¹; Siegel, J.A.¹; Tausch, T.J.¹; Klein, A.¹; Roehrborn, C.G.¹;

Morey, A.F.¹

1: University of Texas Southwestern Medical Center, USA

Scientific Program

* = not CME-certified



096. Increased penile length after inflatable penile prosthesis replacement

Chung, P.H.¹; Siegel, J.A.¹; Mason, R.²; Tausch, T.J.¹; Morey, A.F.¹

1: University of Texas Southwestern Medical Center, USA; 2: Methodist Dallas Medical Center

John J. Mulcahy, MD, PhD, David Ralph, MS, FRCS & Steven K. Wilson, MD

02:35 p.m. - 03:20 p.m.

Controversial point/counterpoint: Cylinders should be upsized

Gerard D. Henry, MD



097. The ED care pathway for patients considering penile implants*

Nelson, C.¹; Hill, R.²; Burnett, A.³; Hakim, L.⁴; Mulhall, J.¹

1: Memorial Sloan Kettering Cancer Center, USA; 2: American Medical Systems, USA; 3: Johns Hopkins Medical Institutions, USA; 4: Cleveland Clinic, USA

Controversial point/counterpoint: Malleable only for washout

Ricardo M. Munarriz, MD

Controversial point/counterpoint: Drain & retain vs removal in non-infected setting

Joshua A. Broghammer, MD



098. Inflatable penile prosthesis implantation is possible under local anesthesia with conscious sedation: Technique and results

Park, S.S.H.¹; Wilson, S.K.²; Morey, A.F.³

1: Sewum Prosthetic Urology Clinic, Korea, South; 2: Editor in Chief ISSM Video Journal of Prosthetic Urology, USA; 3: UT Southwestern Medical Center, Department of Urology, USA

Controversial point/counterpoint: Ectopic reservoir placement should always be used after robot RRP

Edward Karpman, MD

03:20 p.m. - 03:30 p.m.

Update on Penile Fracture Repair

Anthony J. Bella, MD

12:15 p.m. - 01:45 p.m.

Sponsored lunch symposium

Ocean Tower II B/C

01:45 p.m. - 04:10 p.m.

Penile implants

» Concurrent session

Ocean Tower II A

Moderators: Rafael E. Carrion, MD & Run Wang, MD

01:45 p.m. - 02:35 p.m.

The 3 worst cases of my career & What I would have done differently

03:30 p.m. - 03:40 p.m.



Podium presentation: 014.

“Unexpected” corporal fibrosis should be “expected”: the prevalence of significant corporal fibrosis encountered during penile prosthetics

Brant, W.¹; Kohler, T.²; Henry, G.³; Karpman, E.⁴; Kansas, B.⁵; Jones, L.⁶; Christine, B.⁷; Bennett, N.⁸; Khera, M.⁹; Bella, A.¹⁰

1: University of Utah, USA; 2: Southern Illinois University, USA; 3: Regional Urology, USA; 4: El Camino Urology Medical Group, USA; 5: The Urology Team, USA; 6: Urology San Antonio, USA; 7: Urology Centers of Alabama, USA; 8: Lahey Clinic, USA; 9: Baylor College, USA; 10: University of Ottawa, Canada

Scientific Program

* = not CME-certified

03:40 p.m. - 03:50 p.m.



Podium presentation: 015.
Outcomes of IPP placement by surgical approach, penoscrotal vs infrapubic, results from a prospective multicenter study*

Karpman, E.¹; Bella, A.²; Brant, W.³; Kansas, B.⁴; Jones, L.⁵; Kohler, T.⁶; Christine, B.⁷; Bennett, N.⁸; Khera, M.⁹; Henry, G.¹⁰
 1: El Camino Urology Medical Group, Inc, USA; 2: University of Ottawa; 3: University of Utah; 4: The Urology Team; 5: Urology San Antonio; 6: SIU School of Medicine; 7: St. Vincent's Birmingham; 8: Lahey Clinic; 9: Baylor College of Medicine; 10: Regional Urology

03:50 p.m. - 04:00 p.m.



Podium presentation: 016.
MRI analysis of architectural changes of the retropubic space and relevant structures post radical prostatectomy:

Implications for penile prosthesis reservoir placement
Sullivan, J.¹; Foran, P.¹; Nelson, C.¹; Akin, O.¹; Mulhall, J.¹
 1: MSKCC, USA

04:00 p.m. - 04:10 p.m.



Podium presentation: 017.
Reoperation of penile prothetic surgery: A longitudinal analysis of California population database
Mirheydar, H.¹; Hsieh, T.C.¹

1: University of California San Diego Department of Urology, USA

01:45 p.m. - 02:15 p.m.

Basic science research forum

» Concurrent session
 Pompeii Ballroom
 Moderator: Carol A. Podlasek, PhD

01:45 p.m. - 02:00 p.m.

ISSM sponsored – Is there an genetic basis to lifelong premature ejaculation?
 Chris McMahon, MD

02:00 p.m. - 02:15 p.m.

ESSM sponsored – Does microvascular dysfunction explain the pathophysiology of both ED and BPH-LUTS
 Selim Cellek, MD, PhD

02:15 p.m. - 04:10 p.m.

Basic science abstracts

» Concurrent session
 Pompeii Ballroom
 Moderators: Trinity J. Bivalacqua, MD, PhD & Carol A. Podlasek, PhD



Podium presentation: 018.
eNOS uncoupling contributes to earlier erectile dysfunction and endothelial dysfunction in the penis than in the carotid artery in a rat model of type 2 diabetes mellitus

Musicki, B.¹; Hannan, J.¹; Lagoda, G.¹; La Favor, J.¹; Bivalacqua, T.¹; Burnett, A.¹
 1: Johns Hopkins University, USA



Podium presentation: 019.
Sonic hedgehog regulation of collagen in the penis
Podlasek, C.¹; Bond, C.²; McVary, K.³

Scientific Program

* = not CME-certified

1: University of Illinois at Chicago, USA; 2: Northwestern University; 3: SIU



Podium presentation: 020.
Effects of a selective alpha-1a adrenoceptor antagonist, silodosin treatment on erectile dysfunction of rats with partial

bladder outlet obstruction

Gur, S.¹; Kaya, E.¹; Bastaskin, T.¹; Onal, E.¹; Yilmaz, D.¹; Bayatli, N.¹

1: Ankara University School of Pharmacy, Turkey



Podium presentation: 021.
Nanotechnology improved stem cell therapy in erectile

Lin, H.¹; Dhanani, N.; Tseng, H.; Souza, G.; Wang, R.²

1: University of Texas Medical School at Houston, USA; 2: University of Texas Medical School at Houston and MD Anderson Cancer Center, USA



Podium presentation: 022.
Skeletal muscle derived stem cells (MDSC) ameliorate erectile dysfunction in a rat model of type 2 diabetes, but their repair

ability is severely impaired when isolated from long-term diabetic milieu

Kovanecz, I.¹; Vernet, D.²; Masouminia, M.²; Tsao, J.³; Loni, L.²; Victorino, J.²; De Lang, I.²; Rajfer, J.⁴; Gonzalez-Cadavid, N.F.⁵

1: LABioMed Research Institute at Harbor-UCLA and UCLA School of Medicine, USA; 2: LABioMed Research Institute at Harbor-UCLA, USA; 3: Charles Drew University of Medicine and Science, USA; 4: LABioMed Research Institution at Harbor-UCLA, USA and UCLA School of Medicine, USA; 5: LABioMed Research Institute at Harbor-UCLA and UCLA School of Medicine, USA



Podium presentation: 023.

The cyclic AMP-binding protein kinase A (cAK), vasoactive intestinal polypeptide (VIP) and cyclic AMP phosphodiesterase

type 4 (PDE4) are expressed in the human vagina
Ückert, S.¹; Albrecht, K.²; Kuczyk, M.A.¹; Bannowsky, A.³; Hedlund, P.⁴

1: Hannover Medical School, Dept. of Urology & Urological Oncology, Hannover, Germany; 2: Hannover Medical School, Institute for Legal & Forensic Medicine, Hannover, Germany; 3: Osnabrück Municipal Hospital, Dept. of Urology, Osnabrück, Germany; 4: Linköping University, Dept. of Clinical Pharmacology, Linköping, Sweden



Podium presentation: 024.

A role for CTDSPL in fibrosis and plaque calcification in Peyronie's disease

Pastuszak, A.W.¹; Bournat, J.¹;

Lamb, D.J.¹; Lipshultz, L.I.¹

1: Baylor College of Medicine, USA



Podium presentation: 025.

NADPH oxidase inhibition and sepiapterin supplementation fail to ameliorate age-related erectile dysfunction in Lewis rats

Becak, D.P.¹; Jones, E.D.¹; Lust, R.M.¹; Wingard, C.J.¹

1: East Carolina University, USA



Podium presentation: 026.

Differential effects of sildenafil and tadalafil on human penile smooth muscle cells: New insights for old mechanisms

Rezk, B.¹; Moustafa, A.A.²; Sangkum, P.²; Abd Elmageed, Z.Y.²; Sikka, S.²; Abdel Mageed, A.B.²; Hellstrom, W.J.G.²

1: Southern University of New Orleans, USA; 2: Tulane University School of Medicine, USA

Scientific Program

* = not CME-certified



Podium presentation: 027.
Absence of S-nitrosoglutathione reductase alters erectile function through oxidative stress
Lagoda, G.¹; Anele, U.¹; Goetz, T.¹;

Burnett, A.L.¹
1: Johns Hopkins University, USA



Podium presentation: 028.
NELL1: A genetic factor predisposing to fibrosis associated with Peyronie's disease

Pastuszak, A.W.¹; Bournat, J.¹; Lamb, D.J.¹; Lipshultz, L.I.¹
1: Baylor College of Medicine, USA



Podium presentation: 029.
Plasmid-based transient luciferase gene transfer in the major pelvic ganglion assessed with real time live animal imaging*

Sopko, N.A.¹; Cooper, J.¹; Woda, J.²; Matsui, H.¹; Liu, X.¹; Hannan, J.L.¹; Bivalacqua, T.J.¹
1: Johns Hopkins School of Medicine, USA; 2: Juventas Therapeutics, Inc

04:10 p.m. - 04:30 p.m.

ⓘ Break & poster viewing time

📍 *Ocean Tower I*

04:30 p.m. - 05:30 p.m.

ⓘ Podium presentations by past SMSNA grant awardees

» *Concurrent session*
📍 *Pompeii Ballroom*
👤 *Moderators: Michael E. DiSanto, PhD & Johanna Hannan, PhD*

04:30 p.m. - 04:45 p.m.

The role of rho-kinase in peripheral nerve injury induced female sexual dysfunction
Johanna Hannan, PhD

04:45 p.m. - 05:00 p.m.

Development of ED and CVD: Effects of a Western diet and exercise
Justin D. La Favor, PhD

05:00 p.m. - 05:15 p.m.

Arousal incontinence in men following radical prostatectomy
Christian Nelson, PhD

05:15 p.m. - 05:30 p.m.

The benefits of climbing the Matterhorn daily: Normobaric interval hypoxia preserves erectile function and benefits pulse pressure in the aging male SHR
Cynthia M. Pruss, MD

04:30 p.m. - 05:30 p.m.

ⓘ Moderated posters 7 – Implant 2

» *Concurrent session*
📍 *Ocean Tower II A*
👤 *Moderators: Andrew C. Kramer, MD & Ryan Terlecki, MD*



099. Factors associated with treatment satisfaction following penile prosthesis implantation
Khurgin, J.L.¹; Anele, U.¹; Burnett, A.L.¹

1: Johns Hopkins Hospital, USA

Scientific Program

* = not CME-certified



100. Maria Stitch: A novel technique to prevent pump migration in inflatable penile prosthesis

Ramos, L.¹; Maria, P.²

1: Montefiore Medical Center, USA; 2: Montefiore Medical Center



101. “Distal Corporal Anchoring Stitch” a technique to address Distal corporal crossovers and impending lateral extrusions of a penile prosthesis

Rafiei, A.¹; Martinez, D.¹; Suarez Sarimienta, A.²; Bianco, F.³; Antonini, G.⁴; Gheiler, E.³; Carrion, R.⁵; Perito, P.⁶

1: University of South Florida, USA; 2: Department of Urology, Coral Gables Hospital, USA; 3: Miami Urology Specialists, USA; 4: Department of Urology, “Sapienza” Rome University, Italy; 5: University of South Florida, USA; 6: Department of Urology, Coral Gables Hospital, USA



102. Penile prosthesis insertion after radial forearm free flap neophallus

Pariser, J.J.¹; Malik, R.D.¹; Gottlieb, L.J.¹; Bales, G.T.¹

1: University of Chicago, USA



103. Inflatable penile prosthesis implantation in men under 30: Long-term outcomes regarding patient satisfaction

Gross, M.¹; Munarriz, R.¹

1: Boston University Medical Center, USA



104. Maximizing “rigidity factor” of inflatable penile prosthesis (IPP) results in better artificial erection

Cordon, B.H.¹; Eid, J.F.¹

1: Lenox Hill Hospital, USA



105. “Sticky pump” syndrome: Trending towards non-operative treatment of patients with difficult AMS 700-Series IPP inflation

Tausch, T.J.¹; Siegel, J.A.¹; Klein, A.¹; Morey, A.F.¹

1: University of Texas Southwestern Medical Center, USA



106. Use of rear tip extenders does not affect penile implant satisfaction or outcomes

Kohler, T.¹; Brant, W.²; Karpman, E.³; Kansas, B.⁴; Jones, L.⁵;

Christine, B.⁶; Bennett, N.⁷; Khera, M.⁸; Bella, A.⁹; Henry, G.¹⁰

1: Southern Illinois University SOM, USA; 2: University of Utah; 3: El Camino Urology Medical Group; 4: The Urology Team; 5: Urology San Antonio; 6: Urology Centers of Alabama; 7: Lahey Clinic; 8: Baylor College; 9: University of Ottawa, Canada; 10: Regional Urology, USA



107. Penile prosthesis placement in patients with a history of total phallic construction

Zuckerman, J.¹; Smentkowski, K.¹; Gilbert, D.¹; Virasoro, R.¹; Tonkin, J.¹;

Jordan, G.¹; McCammon, K.¹

1: Eastern Virginia Medical School, USA



108. Simultaneous inflatable penile prosthesis and quadratic transobturator male sling procedure

Weinberg, A.¹; Deibert, C.¹;

Hernandez, K.¹; Valenzuela, R.¹

1: Columbia University Medical Center, USA

Scientific Program

* = not CME-certified



109. Utilization of pre-operative penile stretch test as predictor of erection and total implant length
 Ayoub, H.¹; Westney, O.L.¹; Perito, P.E.²

1: MD Anderson Cancer Center, Houston, USA; 2: Perito Urology, Florida, USA



110. Key factors and influencers impacting the penile implant decision*
Nelson, C.¹; Hill, R.²; Burnett, A.³; Hakim, L.⁴; Mulhall, J.¹

1: Memorial Sloan Kettering Cancer Center, USA; 2: American Medical Systems, USA; 3: Johns Hopkins Medical Institutions, USA; 4: Cleveland Clinic, USA

04:30 p.m. - 05:30 p.m.

Moderated posters 8 – Priapism, Reconstruction & FSD

» Concurrent session

📍 Mona Lisa

👤 Moderators: Anthony J. Bella, MD & Andrew T. Goldstein, MD, FACOG



111. How combined serotonin-1A receptor agonist and 2A-receptor antagonist can heal hypoactive sexual desire disorder (HSDD)

Holstege, G.¹
 1: The University of Queensland Australia, Netherlands



112. A randomized, single center, single-blind, crossover thermographic study to evaluate the effect of 1000 mcg of topical alprostadil cream compared to an over-the-counter marketed lubricant

Goldstein, I.¹; Gonzalez, J.R.²; Gagnon, C.²; Minton, J.N.²; Morris, D.³; Goldstein, S.W.²

1: Alvarado Hospital, USA; 2: San Diego Sexual Medicine, USA; 3: Webbwrites, USA



113. Symptomatic and asymptomatic Bartholin cyst formation after complete vestibulectomy for congenital or acquired neuroproliferative vestibulodynia

Cohen, S.D.¹; Gonzalez, J.R.¹; Gagnon, C.¹; Minton, J.N.¹; Espenschied, C.²; Goldstein, I.³

1: San Diego Sexual Medicine, USA; 2: San Diego Sexual Medicine, United States; 3: Alvarado Hospital, USA



114. Artificial urinary sphincter for treatment of incontinence in the elderly

Raup, V.T.¹; Eswara, J.R.²; Geminiani, J.¹; Brandes, S.B.¹

1: Washington University in St. Louis, USA; 2: Brigham and Women's Hospital, Harvard University, USA



115. Location of AUS pressure regulating balloon: Functional outcomes of high submuscular position are equivalent to space of retzius

Singla, N.¹; Simhan, J.¹; Siegel, J.¹; Tausch, T.¹; Morey, A.F.¹

1: University of Texas Southwestern Medical Center, USA



116. Operative management for priapism: A contemporary experience at a single institution

Kappa, S.F.¹; Green, E.A.¹; Joshi, S.¹; Kaufman, M.R.¹; Milam, D.F.¹

1: Vanderbilt University Medical Center, USA

Scientific Program

* = not CME-certified



117. Efficacy and sedation-related safety of Flibanserin in premenopausal women*
Natarajan, K.¹; Sicard, E.²; Kay, G.G.³; Kim, N.N.⁴

1: Sprout Pharmaceuticals, Raleigh, NC; 2: Algorithme Pharma, Montreal, Quebec, Canada; 3: Cognitive Research Corp., Saint Petersburg, FL; 4: Institute for Sexual Medicine, San Diego, CA



118. Persistent Genital Arousal Disorder (PGAD): Experience with management in 35 consecutive cases
Cohen, S.D.¹; Gonzalez, J.R.¹;

Gagnon, C.¹; Minton, J.N.¹; Espenschied, C.²; Goldstein, I.³
 1: San Diego Sexual Medicine, USA; 2: San Diego Sexual Medicine, United States; 3: Alvarado Hospital, USA



119. Penile fracture outcomes: Faux pas du coit at high risk for urethral injury, ED & Peyronies
Butcher, M.¹; Swanson, D.²;

Polackwich, A.S.³; Helfand, B.T.⁴;
Masson, P.⁵; Dugi III, D.³; Hedges, J.³; Kohler, T.¹;
McVary, K.¹
 1: Division of Urology, Southern Illinois University, Springfield, IL, USA; 2: Department of Urology, Oregon health & Science University, Portland, OR, USA; 3: Department of Urology, Oregon health & Science University, Portland, OR, USA; 4: Division of Urology, Department of Surgery, NorthShore University Health; 5: Department of Urology, Feinberg School of medicine, Northeastern Univeristy, Chicago, IL



120. Priapism Impact Profile (PIP) questionnaire: Development and evaluation
Anele, U.¹; Burnett, A.L.¹;
Derogatis, L.R.²

1: The Brady Urological Institute, The Johns Hopkins School of Medicine, USA; 2: Maryland Center for Sexual Health, USA



121. The association between sex hormones and female sexual dysfunction
Chung, W.S.¹; Yoon, H.¹

1: Ewha Womans University School of Medicine, Korea, South



122. Reconstructive armamentarium for correction of adult buried penis syndrome
Tausch, T.J.¹; Westerman, M.E.¹;
Hoxworth, R.¹; Klein, A.¹; Siegel,

J.A.¹; Morey, A.F.¹
 1: University of Texas Southwestern Medical Center, USA

05:30 p.m. - 06:00 p.m.

📌 **SMSNA business meeting**

📍 Pompeii Ballroom

06:00 p.m. - 06:15 p.m.

📌 **SUPS business meeting**

📍 Pompeii Ballroom

06:00 p.m. - 07:00 p.m.

📌 **Young clinicians mixer (on invitation only - more information at registration desk)**


📍 Ocean Tower II Foyer

Scientific Program » Sunday November 23, 2014

* = not CME-certified



07:45 a.m. - 08:00 a.m.

Day introduction and recap of Saturday

 *Pompeii Ballroom*
Tobias S. Köhler, MD, MPH

08:00 a.m. - 09:15 a.m.

Andrologists as educators session

 *Pompeii Ballroom*
 *Moderators: Brian S. Christine, MD & Alan W. Shindel, MD*

08:00 a.m. - 08:10 a.m.

Medical student education

Alan W. Shindel, MD

08:10 a.m. - 08:20 a.m.

Becoming a better educator

Kurt McCammon, MD

08:20 a.m. - 08:30 a.m.

Evolving methods of resident education

Andrew C. Kramer, MD

08:30 a.m. - 08:40 a.m.

The role of cyber technology in education

Brian S. Christine, MD

08:40 a.m. - 08:50 a.m.

Andrology OPRS & giving feedback



Tobias S. Köhler, MD, MPH

08:50 a.m. - 09:15 a.m.

Panel discussion

09:15 a.m. - 10:15 a.m.

Awards & take home messages

 *Pompeii Ballroom*
 *Moderator: Tobias S. Köhler, MD, MPH*

09:15 a.m. - 09:25 a.m.

Awards recap*

William O. Brant, MD

09:25 a.m. - 09:35 a.m.

Psych/Life style/Female

William P. Conners, MD

09:35 a.m. - 09:45 a.m.

Basic science

Carol A. Podlasek, PhD

09:45 a.m. - 09:55 a.m.

Implant

Gregory J. Lowe, MD

09:55 a.m. - 10:05 a.m.

Peyronie's/Reconstruction

Brian S. Christine, MD

10:05 a.m. - 10:15 a.m.

Hypogonadism

Ashley H. Tapscott, DO